What the FDA labels say about taking them together
Clarithromycin and mometasone
Mometasone's FDA label of August 19, 2026 names clarithromycin in its drug interactions (prescription label) section; the clarithromycin label PlainMeds reads does not name mometasone. The mometasone label: “Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ASMANEX HFA with ketoconazole, and other known strong cytochrome P450 (CYP) isoenzyme 3A4 …”
Check it at the source: the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation); the mometasone FDA label on DailyMed (effective August 19, 2026, L. Perrigo Company).
What does the clarithromycin label say about mometasone?
Clarithromycin's label (effective April 9, 2026) does not name mometasone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed
What does the mometasone label say about clarithromycin?
Mometasone label, drug interactions (prescription label)Caution should be exercised when considering the coadministration of mometasone furoate monohydrate nasal spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Clinical Pharmacology (12.3) ].
Asmanex Hfa label (Organon LLC, July 7, 2026), warnings and precautionsInteractions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ASMANEX HFA with ketoconazole, and other known strong cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to mometasone furoate may occur [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
Source: FDA drug label (Asmanex Hfa, NDA205641), Organon LLC, effective July 7, 2026 (SPL set 0c6d63da-41bc-4894-bead-198e66c848ac), via openFDA
Source: FDA drug label (Asmanex, NDA021067), Organon LLC, effective July 7, 2026 (SPL set 10b36fb2-6b0d-4f20-b197-3564d6f594b9), via openFDA
Source: FDA drug label (Nasonex), L. Perrigo Company, effective August 19, 2026 (SPL set 13696a8b-366a-4a5e-adea-d5b7bff9e46f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clarithromycin | Mometasone | |
|---|---|---|
| Labeled for | Bacterial infections, Acid reflux and ulcers | Allergies, Asthma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.466 per tablet 500 mg tablet | $0.354 per gram 0.1% cream |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once